晚期结直肠癌精准分子靶向治疗研究进展

摘要/Abstract

摘要：

结直肠癌是常见的消化系统恶性肿瘤，具有起病隐匿、复发转移风险高、预后差等特点。近年来，针对RAS、BRAF、MMR/MSI、HER2、MET、NTRK、POLE/POLD1等不同分子分型结直肠癌的靶向治疗相关临床研究均取得了一定的成果。此外，结直肠癌分子靶向治疗与其他疗法联合应用的探索也在不断进行。阐明结直肠癌分子靶向治疗作用机制及临床应用进展，可为结直肠癌患者临床治疗方案的制定提供更可靠的依据。

关键词:结直肠肿瘤,分子靶向治疗

Abstract:

Colorectal cancer is a common malignant tumor of the digestive system， with the characteristics of insidious onset， high risk of recurrence and metastasis， and poor prognosis. In recent years， clinical researches related to targeted therapy for colorectal cancer of different molecular subtypes such as RAS， BRAF， MMR/MSI， HER2， MET， NTRK， and POLE/POLD1 have all achieved certain results. Besides， the exploration of the combined application of molecular targeted therapy for colorectal cancer and other therapies is also continuously carried out. Clarifying the mechanism of action and clinical application progress of molecular targeted therapy for colorectal cancer can provide a more reliable basis for formulating clinical treatment plans for colorectal cancer patients.

Key words:Colorectal neoplasms,Molecular targeted therapy

詹海峰, 王文学, 耿嘉蔚. 晚期结直肠癌精准分子靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 601-605.

Zhan Haifeng, Wang Wenxue, Geng Jiawei. Research progress in precise molecular targeted therapy for advanced colorectal cancer[J]. Journal of International Oncology, 2024, 51(9): 601-605.

参考文献39

[1]	Wang S, Zheng R, Li J, et al. Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN[J].Lancet Gastroenterol Hepatol,2024,9(3): 229-237. DOI:10.1016/S2468-1253(23)00366-7.
[2]	中华医学会肿瘤学分会早诊早治学组. 中国结直肠癌早诊早治专家共识(2023版)[J].中华医学杂志,2023,103(48): 3896-3908. DOI:10.3760/cma.j.cn112137-20230804-00164.
[3]	Bando H, Ohtsu A, Yoshino T. Therapeutic landscape and future direction of metastatic colorectal cancer[J].Nat Rev Gastroenterol Hepatol,2023,20(5): 306-322. DOI:10.1038/s41575-022-00736-1. pmid:36670267
[4]	Benson AB, Venook AP, Al-Hawary MM, et al. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2023,21(6): 653-677. DOI:10.6004/jnccn.2023.0030.
[5]	Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J].Ann Oncol,2023,34(1): 10-32. DOI:10.1016/j.annonc.2022.10.003.
[6]	Mi M, Weng S, Xu Z, et al. CSCO guidelines for colorectal cancer version 2023: updates and insights[J].Chin J Cancer Res,2023,35(3): 233-238. DOI:10.21147/j.issn.1000-9604.2023.03.02.
[7]	Lu X, Li Y, Li Y, et al. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis[J].BMC Cancer,2023,23(1): 1117. DOI:10.1186/s12885-023-11600-z.
[8]	Wang C, Sandhu J, Fakih M. Mucinous histology is associated with resistance to anti-EGFR therapy in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer[J].Oncologist,2022,27(2): 104-109. DOI:10.1093/oncolo/oyab028. pmid:35641204
[9]	Nixon AB, Sibley AB, Liu YM, et al. Plasma protein biomarkers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: results from CALGB 80405 (alliance)[J].Clin Cancer Res,2022,28(13): 2779-2788. DOI:10.1158/1078-0432.CCR-21-2389.
[10]	国家卫生健康委员会医政司, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2023版)[J].消化肿瘤杂志(电子版),2023,15(3): 177-206. DOI:10.19538/j.cjps.issn1005-2208.2023.06.02.
[11]	Ciardiello D, Martinelli E, Troiani T, et al. Anti-EGFR rechallenge in patients with refractory ctDNA RAS/BRAF wt metastatic colorectal cancer: a nonrandomized controlled trial[J].JAMA Netw Open,2024,7(4): e245635. DOI:10.1001/jamanetworkopen.2024.5635.
[12]	中国医师协会结直肠肿瘤专业委员会, 中国抗癌协会大肠癌专业委员会, 国家癌症中心国家肿瘤质控中心结直肠癌质控专家委员会. 结直肠癌靶向治疗中国专家共识[J].中华结直肠疾病电子杂志,2022,11(5): 353-360. DOI:10.3877/cma.j.issn.2095-3224.2022.05.001.
[13]	Huang L, Guo Z, Wang F, et al. KRAS mutation: from undruggable to druggable in cancer[J].Signal Transduct Target Ther,2021,6(1): 386. DOI:10.1038/s41392-021-00780-4.
[14]	Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer[J].Cancer Discov,2020,10(8): 1129-1139. DOI:10.1158/2159-8290.CD-20-0187. pmid:32430388
[15]	Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C[J].N Engl J Med,2023,388(1): 44-54. DOI: 10.1056/NEJMoa2212 419.
[16]	Kim D, Herdeis L, Rudolph D, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth[J].Nature,2023,619(7968): 160-166. DOI:10.1038/s41586-023-06123-3.
[17]	Liu JJ, Xie H. BRAF non-V600 mutations in metastatic colorectal cancer[J].Cancers (Basel),2023,15(18): 4604. DOI:10.3390/cancers15184604.
[18]	Grothey A, Fakih M, Tabernero J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines[J].Ann Oncol,2021,32(8): 959-967. DOI:10.1016/j.annonc.2021.03.206. pmid:33836264
[19]	Stintzing S, Heinrich K, Tougeron D, et al. FOLFOXIRI plus cetuximab or bevacizumab as first-line treatment of BRAFV600E-mutant metastatic colorectal cancer: the randomized phase Ⅱ FIRE-4.5 (AIO KRK0116) study[J].J Clin Oncol,2023,41(25): 4143-4153. DOI:10.1200/JCO.22.01420.
[20]	Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer[J].N Engl J Med,2019,381(17): 1632-1643. DOI:10.1056/NEJMoa1908075.
[21]	徐良富, 李袁飞. MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J].国际肿瘤学杂志,2023,50(3): 186-190. DOI:10.3760/cma.j.cn371439-20221213-00037.
[22]	Zhang Q, Li J, Shen L, et al. Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer[J].Cancer Biol Med,2023,20(10): 706-712. DOI:10.20892/j.issn.2095-3941.2023.0240.
[23]	Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential[J].Nat Rev Gastroenterol Hepatol,2019,16(6): 361-375. DOI:10.1038/s41575-019-0126-x. pmid:30886395
[24]	Shu Y, Zheng S. The current status and prospect of immunotherapy in colorectal cancer[J].Clin Transl Oncol,2024,26(1): 39-51. DOI:10.1007/s12094-023-03235-0.
[25]	Huang Y, Jia W, Zhao G, et al. Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer[J].Chin Clin Oncol,2024,13(1): 3. DOI:10.21037/cco-23-117.
[26]	Strickler JH, Yoshino T, Graham RP, et al. Diagnosis and treatment of ERBB2-positive metastatic colorectal cancer: a review[J].JAMA Oncol,2022,8(5): 760-769. DOI:10.1001/jamaoncol.2021.8196. pmid:35238866
[27]	Spitzer E, Cervera P, André T, et al. Targeting HER2 in colorectal cancer[J].Bull Cancer,2023,110(4): 402-411. DOI:10.1016/j.bulcan.2023.01.013.
[28]	Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study[J].Lancet Oncol,2023,24(5): 496-508. DOI:10.1016/S1470-2045(23)00150-X. pmid:37142372
[29]	Fu X, Ying J, Yang L, et al. Dual targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: a phase 2 trial[J].Cancer Sci,2023,114(3): 1067-1074. DOI:10.1111/cas.15660.
[30]	Akhmetkaliyev A, Alibrahim N, Shafiee D, et al. EMT/Met plasticity in cancer and go-or-grow decisions in quiescence: the two sides of the same coin?[J].Mol Cancer,2023,22(1): 90. DOI:10.1186/s12943-023-01793-z.
[31]	Levantini E, Maroni G, Del Re M, et al. EGFR signaling pathway as therapeutic target in human cancers[J].Semin Cancer Biol,2022,85: 253-275. DOI:10.1016/j.semcancer.2022.04.002. pmid:35427766
[32]	Rimassa L, Bozzarelli S, Pietrantonio F, et al. Phase Ⅱ study of tivantinib and cetuximab in patients with KRAS wild-type metastatic colorectal cancer with acquired resistance to EGFR inhibitors and emergence of met overexpression: lesson learned for future trials with EGFR/met dual inhibition[J].Clin Colorectal Cancer,2019,18(2): 125-132.e2. DOI:10.1016/j.clcc.2019.02.004.
[33]	Strickler JH, Rushing CN, Uronis HE, et al. Cabozantinib and panitumumab for RAS wild-type metastatic colorectal cancer[J].Oncologist,2021,26(6): 465-e917. DOI:10.1002/onco.13678.
[34]	Qi C, Zhou T, Bai Y, et al. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment[J].Int J Cancer,2023,153(11): 1916-1927. DOI:10.1002/ijc.34522.
[35]	Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials[J].Lancet Oncol,2020,21(2): 271-282. DOI:10.1016/S1470-2045(19)30691-6. pmid:31838007
[36]	Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials[J].Lancet Oncol,2020,21(4): 531-540. DOI:10.1016/S1470-2045(19)30856-3. pmid:32105622
[37]	Koh G, Degasperi A, Zou X, et al. Mutational signatures: emerging concepts, caveats and clinical applications[J].Nat Rev Cancer,2021,21(10): 619-637. DOI:10.1038/s41568-021-00377-7. pmid:34316057
[38]	Wang F, Zhao Q, Wang Y, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types[J].JAMA Oncol,2019,5(10): 1504-1506. DOI:10.1001/jamaoncol.2019.2963.
[39]	Garmezy B, Gheeya J, Lin HY, et al. Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers[J].JCO Precis Oncol,2022,6: e2100267. DOI:10.1200/PO.21.00267.